Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

Immuron increases Travelan sales in third quarter by 16% to AUD 1.5m

Immuron reports Travelan sales of AUD 1.5 million in the third quarter, up 16% year-on-year, and cumulative sales of AUD 5.7 million to March 2026 (+7%). Australia contributed AUD 0.9m (+15%) and the US AUD 0.5m (+1%), with currency effects weighing on US growth. Quarterly sales in Canada rose 82% after initial sales via Jean Coutu, but cumulative Canadian sales remain well below last year. Despite revenue growth, the company was unprofitable over the past twelve months and consumed cash, though it has a current ratio of 1.8. Sales figures are unaudited. » Altro su de.investing.com
Immuron shares tumble after ETEC trial fails to meet primary endpoint

Immuron shares fell 25.8% after a clinical trial of an ETEC hyperimmune bovine colostrum product failed to reach statistical significance for its primary endpoint. The study, conducted by the Uniformed Services University, tested a product manufactured and administered outside Immuron’s Travelan protocol; the company said the results do not reflect Travelan’s performance. Separately, the FDA cleared Immuron’s IMM-529 for a phase 2 trial targeting Clostridioides difficile, with the study expected to start in the first half of 2026 and enroll up to 60 participants. » Altro su finance.yahoo.com
Immuron share plunges after study misses primary endpoint

Immuron shares fell about 24.5% pre-market after a study conducted by the Uniformed Services University of the hyperimmune bovine colostrum product (IMM-124E) against ETEC missed its primary endpoint. Immuron stresses the tested preparation was not manufactured by the company and differs in dosage and administration from Travelan®, for which thrice-daily dosing is recommended. The company cites possible factors such as delayed dosing starts, protocol deviations and omissions, and says it will proceed with the planned end-of-phase-2 meeting with the FDA. Immuron remains committed to other development programs with the Naval Medical Research Command and the Walter Reed Army Institute of Research, is in talks about tests against EAEC and EPEC strains, and recently raised A$3.5m through a share placement. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Immuron ha registrato ricavi pari a 2,38 Mln € e un utile netto di -1,09 Mln €

(EUR)	dic 2025	YoY
Ricavi	2,38 Mln	-
Utile lordo	1,51 Mln	-
Utile netto	-1,09 Mln	-
EBITDA	-1,31 Mln	-

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	5,9 Mln €
Numero di azioni	257,83 Mln
Massimo/minimo a 52 settimane	0,0606 € - 0,0161 €
Dividendi	No
Beta	0,51
Rapporto P/E	-1,98
Rapporto PEG	-0,04
Rapporto P/B	0,78
Rapporto P/S	1,28

Profilo aziendale

Immuron Limited, ein biopharmazeutisches Unternehmen, erforscht, entwickelt und vermarktet polyklonale Antikörper in Australien, den Vereinigten Staaten und international. Das Unternehmen ist in zwei Segmenten tätig: Forschung und Entwicklung sowie Hyperimmunprodukte. Es vermarktet Travelan, ein rezeptfreies Medikament zur Verringerung des Risikos von Reisedurchfall und zur Linderung der Symptome kleinerer Magen-Darm-Beschwerden, sowie ein Nahrungsergänzungsmittel zum Schutz des Verdauungstrakts; und Protectyn, ein Immunpräparat zur Erhaltung einer gesunden Verdauungsfunktion und Leber. Das Unternehmen entwickelt außerdem Travelan (IMM-124E), das sich in klinischen Phase-III-Studien befindet, um das Risiko einer Reisediarrhöe zu verringern, und als antivirales Mittel gegen SARS-CoV-2 wirkt; und IMM-529, das sich in der klinischen Entwicklungsphase befindet und auf die Behandlung von Patienten mit wiederkehrenden Clostridium-difficile-Infektionen ausgerichtet ist. Das Unternehmen hat eine Forschungsvereinbarung mit dem Naval Medical Research Center zur Entwicklung und klinischen Bewertung eines Therapeutikums gegen Campylobacter- und ETEC-Infektionen und eine Kooperationsvereinbarung mit dem Walter Reed Army Institute of Research zur Entwicklung eines oralen Therapeutikums gegen Shigellose. Immuron Limited wurde 1994 gegründet und hat seinen Sitz in Carlton, Australien.